1. Home
  2. ALVO vs GERN Comparison

ALVO vs GERN Comparison

Compare ALVO & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alvotech

ALVO

Alvotech

HOLD

Current Price

$4.07

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.47

Market Cap

911.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALVO
GERN
Founded
2013
1990
Country
Luxembourg
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
911.0M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
ALVO
GERN
Price
$4.07
$1.47
Analyst Decision
Buy
Hold
Analyst Count
4
3
Target Price
$8.00
$2.17
AVG Volume (30 Days)
828.9K
10.4M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.85
EPS
N/A
N/A
Revenue
N/A
$1,065,000.00
Revenue This Year
$13.28
$26.91
Revenue Next Year
$18.63
$43.75
P/E Ratio
$18.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.94
$1.04
52 Week High
$9.25
$2.01

Technical Indicators

Market Signals
Indicator
ALVO
GERN
Relative Strength Index (RSI) 62.51 50.89
Support Level $3.10 $1.44
Resistance Level $4.59 $1.69
Average True Range (ATR) 0.23 0.11
MACD 0.06 0.01
Stochastic Oscillator 88.55 56.98

Price Performance

Historical Comparison
ALVO
GERN

About ALVO Alvotech

Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: